Good Therapeutics

Good Therapeutics is a biopharmaceutical company focused on producing a new type of drug that provides effective activity only where needed. The company’s regulated, context-dependent molecules combine sensor components targeting specific markers with therapeutic components that are activated only when the sensor binds to its target. While Good Therapeutics’ technology is applicable across a wide range of therapeutic areas, including oncology, metabolic disorders, autoimmune conditions, and pain management, the company is currently developing a series of drugs aimed at addressing unmet cancer needs, with an initial focus on modulated, environment-dependent immune cytokines. The company’s lead program is a PD-1-modulated IL-2 molecule, which can specifically direct IL-2 activity to immune cells capable of recognizing tumor cells without affecting non-target cells. The expected outcome is a therapy with a broader therapeutic effect than existing checkpoint drugs.